Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus.
about
Emerging Vaccine TechnologiesThe use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infectionStructure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial VirusStructural basis of respiratory syncytial virus neutralization by motavizumabStructure of a Major Antigenic Site on the Respiratory Syncytial Virus Fusion Glycoprotein in Complex with Neutralizing Antibody 101FDesign and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial VirusStructural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titersStructure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing EpitopesStructure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing AntibodyAnalysis of Human RSV Immunity at the Molecular Level: Learning from the Past and PresentRSV fusion: time for a new modelRespiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment.GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion ProcessA peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo.Prophylactic administration of a complementarity-determining region derived from a neutralizing monoclonal antibody is effective against respiratory syncytial virus infection in BALB/c mice.Priming with a secreted form of the fusion protein of respiratory syncytial virus (RSV) promotes interleukin-4 (IL-4) and IL-5 production but not pulmonary eosinophilia following RSV challengeCharacterization of an experimental vaccine for bovine respiratory syncytial virus.Characterization of neutralizing affinity-matured human respiratory syncytial virus F binding antibodies in the sub-picomolar affinity range.Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis.Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus diseaseVaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodiesRecombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV diseasePeptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 moleculePalivizumab epitope-displaying virus-like particles protect rodents from RSV challenge.Cholesterol-rich microdomains as docking platforms for respiratory syncytial virus in normal human bronchial epithelial cellsStability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein.Characteristics of RSV-Specific Maternal Antibodies in Plasma of Hospitalized, Acute RSV Patients under Three Months of AgeVirus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B.Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia.Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection.Conformational studies of a short linear peptide corresponding to a major conserved neutralizing epitope of human respiratory syncytial virus fusion glycoprotein.Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeresStructural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donorsProspects for defined epitope vaccines for respiratory syncytial virus.Identification of protein regions involved in the interaction of human respiratory syncytial virus phosphoprotein and nucleoprotein: significance for nucleocapsid assembly and formation of cytoplasmic inclusions.Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein.Recent advances in the development of subunit-based RSV vaccines.Respiratory Syncytial Virus: The Influence of Serotype and Genotype Variability on Clinical Course of Infection.
P2860
Q26783764-2FC96B9A-128C-428E-BC70-D700BF826042Q26864494-5D8A8C23-1257-47B8-9712-018217ABC7B8Q27333522-52DE6C07-EE5F-4950-BB6A-D9CDD1D84D0FQ27659146-7E99B4CA-2E02-4BD4-B906-74565F7F23D2Q27664797-2438A697-D0D7-4565-8B9E-EA0A36157C60Q27667750-DD1A9007-27DA-4D54-B43A-3F086E8B41DCQ27667876-62722D2B-DD07-4C2B-8BBD-E39C0342E99BQ27668015-348E489B-C3C5-4E08-A67C-499F9ACB7279Q27677570-A19726FD-70BF-4A33-8DDF-BBEFAA2E6C84Q28080556-E50BF693-7E34-4E8E-9FAC-B37F454F20F8Q28287657-B24C3043-F87A-4383-903F-9393445DA071Q30240274-A98B33C9-3E3C-45EA-9241-70BDFFF42CE0Q30375062-F5B13A9C-D156-4C15-9DFB-615F11503CE3Q32099239-21188CEB-276D-4B71-8B40-1352F9BD9ACBQ33782181-E38DA049-F6F6-4386-AC01-0C17F85BB1F7Q33825073-EE52B7CC-73A4-4E20-B19A-039EADBA2C29Q33899379-0892A684-80EC-4D02-96C9-13B2888268E8Q34191108-AC373947-5381-4D82-877A-93B5922A1378Q34224973-DCC56555-1938-46BF-9320-B5F8F08ED4E5Q34330690-F5016E0D-B518-45A4-8B64-A98344CEAD79Q34425648-D3BDF080-7106-4E5D-874E-1E3CAE19E4B7Q35070176-C0AA7279-063D-463F-86B6-FA3F21134122Q35488811-6674FB09-3635-4E0B-A3CD-B8AB1E5FE97DQ35535626-D8394560-6205-4F00-BF75-0D5FCEBC5FD6Q35689697-402B001C-6069-4EE4-A750-B43D39F6164CQ36169170-0403D34A-480E-463F-ADE9-4627AA191A05Q36263882-A839AC1E-F354-4337-A4BA-3358E459DC9FQ36281893-23D1F055-9D59-4E5D-AD40-ACA47060323AQ36348462-005A5276-DC3F-4C35-ACAC-20E6FF30DFD9Q36400958-09FBFDC4-98D1-459C-8D30-104BD4BD5247Q36438987-A09B4D7C-0DFA-4AD9-BCF3-D777D39E8909Q36823304-A4E588C5-37A3-4A57-8F7E-84B977807E70Q37242405-B8DFFFAC-C34C-46A2-8232-5F931CF4C9CEQ37536191-F4B14E6E-2F85-4906-8EB5-1494DEBE7AF7Q37593886-6AEF738F-40C1-41A4-893A-A06FB0C993D1Q37721415-9B33CA3A-65CE-4EC5-8218-FA313A739D4BQ38362415-17A17466-9F7E-4E16-8874-A02AEF3710C5Q38394731-FFE7E2EF-AD00-4173-9504-A1D4702AEC89Q38617302-E4E94807-F059-48F9-853E-8EB180D86BC5Q38637248-E81BDAB5-313E-4E56-983B-2C7C3492AEFC
P2860
Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus.
description
1992 nî lūn-bûn
@nan
1992 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Characterization of two antige ...... n respiratory syncytial virus.
@ast
Characterization of two antige ...... n respiratory syncytial virus.
@en
type
label
Characterization of two antige ...... n respiratory syncytial virus.
@ast
Characterization of two antige ...... n respiratory syncytial virus.
@en
prefLabel
Characterization of two antige ...... n respiratory syncytial virus.
@ast
Characterization of two antige ...... n respiratory syncytial virus.
@en
P2093
P1476
Characterization of two antige ...... n respiratory syncytial virus.
@en
P2093
Sullender W
P304
P356
10.1099/0022-1317-73-9-2225
P407
P478
73 ( Pt 9)
P577
1992-09-01T00:00:00Z